BioPharm Intl

Talking biopharmaceuticals, biotechnology, bioprocessing and related pharma manufacturing.

[BioPharm Intl @BioPharmIntl]

Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap.

Get the full industry report at https://t.co/xZJqIJbLID

#AI

[BioPharm Intl @BioPharmIntl]

CAR-T changed blood cancer care.

Solid and brain tumors are a different challenge: cells must reach, penetrate, and survive inside a physical tumor mass.

🔗 See the 3 barriers in the way, free with sign-in: https://t.co/Hx92Ab3WQd

#BioPharm #CARTCells #Oncology

[BioPharm Intl @BioPharmIntl]

One company’s reason to walk away is another’s opportunity.

When Big Pharma drops a drug candidate, smaller developers are often the ones who pick it up, but a second chance isn’t a guarantee.

Get the free FAQ here➡️ https://t.co/10ueVMeiKU

#BioPharm #DrugDevelopment

[BioPharm Intl @BioPharmIntl]

Dr Karu Sukuru of @Catalent_ explains why patient-centric formulation design is advancing oral peptide drug development, a theme from his #PharmSci360 talk. @AAPSComms

🎥 Watch now: https://t.co/IJ9A5L9KHj

#PeptideDrugDelivery #FormulationDevelopment #AAPS2026

[BioPharm Intl @BioPharmIntl]

Drug developers are increasingly treating their suppliers as strategic partners.
Meeta Gulyani of @Ecolab on why that’s changing & where biomanufacturing is headed next.
📽️ Hear the trends shaping bioprocessing https://t.co/LPK49A0Fdr
#BioProcessing

[BioPharm Intl @BioPharmIntl]

Can AI predict which drug molecules fit platform formulations? AI-guided formulation development depends on high-quality data and stability outcomes, says @pfizer's Dr Johnson at #PharmSci360.

🎥 Learn more: https://t.co/zhua07Kbzo

#AIinDrugDevelopment #FormulationScience

[BioPharm Intl @BioPharmIntl]

In today's The BioPharm Brief: New clinical data highlight ADCs in cancer and CAR T-cell therapy for multiple sclerosis, including survival gains, modest benefit, and safety risks.

🎧 Listen: https://t.co/gbxL3cxaaF

#DrugDevelopment #CARTCellTherapy

[BioPharm Intl @BioPharmIntl]

How can pharma entrepreneurship reshape drug development economics? At #AAPS2026 #PharmSci360, @averincapital's @DavidBerry26 will explore innovation and investment in life sciences at the closing plenary.

Read more: https://t.co/oewdVaw15B

#DrugDevelopment #PharmaInnovation

[BioPharm Intl @BioPharmIntl]

Would your bispecific program hold up in a tech transfer tomorrow? Mispaired species and aggregation cut yield and investor confidence.

How to catch them early, with FUJIFILM Biotechnologies: https://t.co/dJVpYEtscw

[BioPharm Intl @BioPharmIntl]

Cell therapy developers are pivoting from ex vivo to in vivo CAR-T.

A 2026 review projects in vivo could cut treatment-course costs by 50% or more. Still a projection.

🔗 What in vivo still has to prove (free sign-in): https://t.co/nLSLvWPxz6

#BioPharm #CellTherapy

[BioPharm Intl @BioPharmIntl]

Can we trust agentic AI for risk assessment? Traceable evidence, transparent decisions, and verifiable outcomes are essential.

🎥 Learn more from Insilica CEO Thomas Luechtefeld ahead of @AAPSComms #PharmSci360: https://t.co/uHsLJH8dln

#AgenticAI #DrugDevelopment

[BioPharm Intl @BioPharmIntl]

How can biomarker testing improve access to targeted cancer therapies? @bmsnews’s Dr @n8pennell explains key barriers in precision oncology, from tissue collection to patient education.

🎥 Learn more: https://t.co/FA5mio208o

#PrecisionOncology #BiomarkerTesting #CancerResearch

[BioPharm Intl @BioPharmIntl]

At #ACG2026, @Odyssey_Tx is presenting a phase 2a trial design evaluating oral RIPK2 inhibitor OD-001 plus vedolizumab in moderate-to-severe UC. Topline induction results are expected in H2 2027.

👉 Read now: https://t.co/Dl2Zu2PjvQ

#UlcerativeColitis #DrugDevelopment

[BioPharm Intl @BioPharmIntl]

Today's BioPharm Brief covers FDA-approved atezolizumab for stage 3 dMMR colon cancer, positive phase 3 data for thyroid eye disease, and petrelintide’s weight-loss results in phase 2b testing.

🎧 Listen now: https://t.co/HpLaX4Oq8n

#DrugDevelopment #ClinicalTrials #Biopharma

[BioPharm Intl @BioPharmIntl]

Dr. Nathan Pennell of Bristol Myers Squibb explains why MRD-negative complete response matters as longer patient survival delays traditional clinical trial endpoints.

🎥 Watch his interview now: https://t.co/MrszoBa0Fo

#MultipleMyeloma #ClinicalTrials

[BioPharm Intl @BioPharmIntl]

The latest BioPharm Brief covers rare disease drug development: @RocketPharma’s RP-A501 gene therapy trial, $47M for cell-based mRNA manufacturing, and @ultragenyx’s $210M FDA priority review voucher sale.

🎧 Listen now! https://t.co/u2dbpxW7OG

#GeneTherapy #RareDisease

[BioPharm Intl @BioPharmIntl]

Our latest podcast covers @FDA breakthrough designations for @abbvie’s Temab-A, expanded biosimilar manufacturing, @Celltrioninc’s Omlyclo launch, and @CaribouBio’s allogeneic CAR-T setback.

🎧 Listen now: https://t.co/U7rnLFwvTW

#Biopharma #DrugDevelopment #CellTherapy

[BioPharm Intl @BioPharmIntl]

On today's podcast, The BioPharm Brief covers AL050 for Parkinson disease, a rare kidney disease partnership, VK2735 obesity dosing strategies, and phase 3 lymphoma data for epcoritamab + R-CHOP.

🎧 Listen now: https://t.co/q0Y9zJgIXg

#Biopharma #DrugDevelopment #ClinicalTrials

[BioPharm Intl @BioPharmIntl]

@genentech secured worldwide rights to @AlectorTx’s investigational AL050, a brain-penetrant GCase enzyme replacement therapy for Parkinson disease. The therapy targets GCase deficiency and neurodegeneration.

👉 Read more: https://t.co/UTFugwnrcZ

#Parkinsons #DrugDevelopment

[BioPharm Intl @BioPharmIntl]

Our latest podcast covers new obesity data for survodutide, expanded biosimilar capacity, an FDA review delay tied to facility remediation, and longer-term litifilimab data. 🎧 Listen to the latest episode: https://t.co/GWjgN1xbBk

#Biopharma #DrugDevelopment #ClinicalTrials

[BioPharm Intl @BioPharmIntl]

How does peptide length affect drug development and influence its regulation? Hear what LumaLex Law's Dustin Robinson has to say.

👉 Watch the full interview to learn more: https://t.co/w4FkPZujKE

#PeptideDrugs #DrugDevelopment #Biopharmaceuticals